Skip to content

A pilot study to evaluate the effects of the lactoferrin formulation on bone mineral density in postmenopausal females

A pilot study to evaluate the effects of the lactoferrin formulation on bone mineral density in postmenopausal females - A pilot study to evaluate the effects of the lactoferrin formulation on bone mineral density in postmenopausal females

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040966
Enrollment
8
Registered
2020-07-19
Start date
2020-07-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Intake of test food for 24 weeks

Sponsors

Soiken Inc.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Females aged 50-69 years who experienced natural menopause over a year ago 2) Subjects whose levels of bone mineral density measurement are more than Young Adult Mean (YAM) -2.5 SD and less than YAM -1.0 SD 3) Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent

Exclusion criteria

Exclusion criteria: 1) Subjects receiving medical treatments for osteoporosis 2) Subjects with serious cardio-vascular, hepatic, renal, respiratory, endocrine, metabolic disorders or a medical history of these disorders 3) Subjects who take regularly pharmaceuticals and quasi-drugs which have the efficacy for bone mineral density or bone metabolism 4) Subjects who take regularly Foods for Specified Health Uses, Foods with Function Claims and supplements which have the possibility of the effects on bone mineral density or bone metabolism 5) Subjects who have the possibility of developing allergic symptoms by the test food 6) Subjects having blood sample of 200 ml or more taken within one month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood) 7) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study 8) Subjects deemed unsuitable by the investigator

Design outcomes

Primary

MeasureTime frame
Bone mineral density (lumber spine (L2-L4), proximal femur)

Secondary

MeasureTime frame
Blood analysis (BAP, TRACP-5b, NTX)

Countries

Japan

Contacts

Public ContactTomohiro Sugino

Soiken Inc. R&D Division

sugino@soiken.com06-6871-8888

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026